|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 3. Association of clinicopathological features and the collective molecular subgroups with a focus on the Asian population** | | | | | | |
|  | Molecular Subtypes | | | | Total | *P* value |
|  | WNT | SHH | Group3 | Group4 |
| Frequency N (%) | 132 (14.88%) | 253 (28.52%) | 115 (12.97%) | 387 (43.63%) | 887 (100.00%) |  |
| Age | | | | | | |
| mean (SD) | 10.077 (4.812) | 10.370 (10.911) | 7.359 (5.058) | 8.713 (4.801) | 9.214 (7.190) | 0.0004\*\*\* |
| median (Q1, Q3) | 9 (7, 12) | 7 (4, 12) | 6.2 (4, 9.5) | 8 (6, 11) | 8 (5, 11) | <0.0001\*\*\*\* |
| Sex | | | | | | |
| M | 58 (43.94%) | 165 (65.22%) | 78 (67.83%) | 277 (71.58%) | 578 (65.16%) | <0.0001\*\*\*\* |
| F | 74 (56.06%) | 88 (34.78%) | 37 (32.17%) | 110 (28.42%) | 309 (34.84%) |  |
| Total | 132 (100.00%) | 253 (100.00%) | 115 (100.00%) | 387 (100.00%) | 887 (100.00%) |  |
| Race | | | | | | |
| Asian | 124 (93.94%) | 220 (86.96%) | 94 (81.74%) | 336 (86.82%) | 774 (87.26%) | 0.0656 |
| Black or African American | 1 (0.76%) | 0 (0.00%) | 0 (0.00%) | 4 (1.03%) | 5 (0.56%) |  |
| White | 5 (3.79%) | 21 (8.30%) | 16 (13.91%) | 37 (9.56%) | 79 (8.91%) |  |
| Other or Not Reported | 2 (1.52%) | 12 (4.74%) | 5 (4.35%) | 10 (2.58%) | 29 (3.27%) |  |
| Total | 132 (100.00%) | 253 (100.00%) | 115 (100.00%) | 387 (100.00%) | 887 (100.00%) |  |
| Tumor texture | | | | | | |
| Hard | 11 (9.02%) | 47 (22.07%) | 20 (21.28%) | 51 (15.18%) | 129 (16.86%) | 0.0018\*\* |
| Mixed | 17 (13.93%) | 52 (24.41%) | 17 (18.09%) | 73 (21.73%) | 159 (20.78%) |  |
| Soft | 94 (77.05%) | 114 (53.52%) | 57 (60.64%) | 212 (63.10%) | 477 (62.35%) |  |
| Total | 122 (100.00%) | 213 (100.00%) | 94 (100.00%) | 336 (100.00%) | 765 (100.00%) |  |
| Histological Subtypes | | | | | | |
| Classic | 106 (91.38%) | 84 (37.50%) | 67 (78.82%) | 269 (82.52%) | 526 (70.04%) | <0.0001\*\*\*\* |
| DN | 4 (3.45%) | 103 (45.98%) | 8 (9.41%) | 48 (14.72%) | 163 (21.70%) |  |
| LCA | 2 (1.72%) | 12 (5.36%) | 9 (10.59%) | 8 (2.45%) | 31 (4.13%) |  |
| MBEN | 4 (3.45%) | 25 (11.16%) | 1 (1.18%) | 1 (0.31%) | 31 (4.13%) |  |
| Total | 116 (100.00%) | 224 (100.00%) | 85 (100.00%) | 326 (100.00%) | 751 (100.00%) |  |
| LCA-enrichment (%) | 1.72% | 5.36% | 10.59% | 2.45% | 4.03% | 0.0055\*\* |
| Extent of tumor resection | | | | | | |
| GTR | 74 (57.81%) | 133 (56.36%) | 56 (53.85%) | 195 (55.40%) | 458 (55.85%) | 0.9314 |
| NTR | 47 (36.72%) | 90 (38.14%) | 39 (37.50%) | 131 (37.22%) | 307 (37.44%) |  |
| STR | 7 (5.47%) | 13 (5.51%) | 9 (8.65%) | 26 (7.39%) | 55 (6.71%) |  |
| Total | 128 (100.00%) | 236 (100.00%) | 104 (100.00%) | 352 (100.00%) | 820 (100.00%) |  |
| Radiotherapy | | | | | | |
| Y | 114 (95.00%) | 180 (82.19%) | 71 (80.68%) | 295 (93.35%) | 660 (88.83%) | <0.0001\*\*\*\* |
| N | 6 (5.00%) | 39 (17.81%) | 17 (19.32%) | 21 (6.65%) | 83 (11.17%) |  |
| Total | 120 (100.00%) | 219 (100.00%) | 88 (100.00%) | 316 (100.00%) | 743 (100.00%) |  |
| Chemotherapy | | | | | | |
| Y | 98 (85.96%) | 186 (85.71%) | 65 (78.31%) | 275 (89.00%) | 624 (86.31%) | 0.001\*\*\* |
| N | 16 (14.04%) | 31 (14.29%) | 18 (21.69%) | 34 (11.00%) | 99 (13.69%) |  |
| Total | 114 (100.00%) | 217 (100.00%) | 83 (100.00%) | 309 (100.00%) | 723 (100.00%) |  |
| Survival probability | | | | | | |
| 1-year OS (%) | 96.1% | 90.3% | 76.6% | 91.7% | 90.9% | 0.00014\*\*\* |
| 2-year OS (%) | 91.7% | 79.3% | 70.6% | 86.1% | 83.9% |  |
| 3-year OS (%) | 91.7% | 68.0% | 67.9% | 74.7% | 75.6% |  |
| 4-year OS (%) | 88.3% | 63.5% | 64.2% | 68.7% | 71.0% |  |
| 5-year OS (%) | 88.3% | 59.8% | 64.2% | 65.2% | 68.0% |  |
| Survival status | | | | | | |
| Alive | 124 (93.94%) | 197 (77.87%) | 84 (73.04%) | 315 (81.40%) | 720 (81.17%) | 0.0001\*\*\*\* |
| Decease | 8 (6.06%) | 56 (22.13%) | 31 (26.96%) | 72 (18.60%) | 167 (18.83%) |  |
| Total | 132 (100.00%) | 253 (100.00%) | 115 (100.00%) | 387 (100.00%) | 887 (100.00%) |  |
| NOTE: \**P* = 0.01-0.05, \*\**P* = 0.001-0.01, \*\*\**P* = 0.001-0.0001, \*\*\*\**P* = <0.0001. | | | | | | |